MORFFI
Dead / Cancelled — Cancelled — Section 8 (as of 25 Apr 2025)
What this means for you
This registration has been cancelled; it no longer blocks anyone on its own. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 87222158
- Registration number
- 5578007
- Mark type
- Stylized text
- Filed
- 01 Nov 2016
- Published for opposition
- 16 Jan 2018
- Registered
- 09 Oct 2018
- Attorney of record
- Nicole M. Meyer
Goods and services
- Class 001 — Chemicals: Chemical products in the nature of chemicals for use in industry and science; chemicals and chemical reagents for non-medical laboratory use; chemicals, reagents, immunoassay preparations and substances for testing blood, bodily fluids samples, antibodies and purified agents for diagnostic purposes; chemicals, reagents, chemical preparations, and chemical substances all for use in analysis and testing in laboratories other than for medical or veterinary purposes; reagents in kit form for performing assays for scientific and research use; chemical substances and immunoassays in the nature of assays for use in diagnostic kits for research purposes; diagnostic reagents for scientific and research use; exogenous antigen, endogenous antigen and autoantigen agents for activating cellular functions; proteins for scientific and research use; immunoassays in the nature of chemical tests used to detect or quantify analytes using an immunological reaction; cell culture proteins for scientific and research use; monoclonal antibodies for in vitro scientific and research use; antigens, namely, exogenous antigens, endogenous antigens, and autoantigens for scientific and medical research use; enzymes for in vitro, scientific, and research use; transferrin, namely, glycoproteins; albumin for scientific and research purposes; human antigens, namely, exogenous antigens, endogenous antigens, and autoantigens for scientific and medical research use; human and animal plasma for scientific and medical research use; human and animal serum, namely, albumin and bovine serum for scientific and medical research use; chemical agents for use in separation for scientific and research use; cell culture media for use in separation techniques for scientific and research use; chemicals and chemical reagents for diagnostic laboratory use
- Class 005 — Pharmaceuticals: Chemicals and chemical reagents for medical use; chemicals, reagents, chemical preparations, and chemical substances all for use in analysis and testing in laboratories for medical and medical diagnostic purposes; reagents in kit form for performing assays for diagnostic and medical purposes; diagnostic reagents for diagnostic and medical use; proteins for diagnostic and medical use; cell culture proteins for diagnostic and medical use; monoclonal antibodies for diagnostic and medical use; enzymes for diagnostic and medical use; albumin for diagnostic and medical use; human and animal blood plasma; chemicals agents for use in separation for diagnostic and medical use; cell culture media for use in separation techniques for diagnostic and medical use
- Class 040 — Treatment of materials: Custom manufacturing services of goods relating to conjugate blocking technology; custom manufacturing services of goods relating to assays and lateral flow assays and enhancement and performance of lateral flow assays
- Class 042 — Scientific and technological services: Scientific and technological development services and research and design relating thereto in the field of lateral flow immunoassays and conjugate blocking technology; scientific and technological services, namely, custom conjugation, lateral flow assay development, lateral flow assay creation, and research and design relating to conjugate blocking technology; scientific and technological services, namely, design and research relating to lateral flow conjugation processes; scientific and technological services, namely, design and research relating to the enhancement and performance of lateral flow assays; industrial analysis and research services for the enhancement and performance of lateral flow assays; diagnostic and medical laboratory services; chemical analysis and research for others; diagnostic medical testing for medical, scientific and research purposes; diagnostic medical testing relating to assays for diagnostic, medical and research purposes; diagnostic medical testing relating to conjugate blocking technology for diagnostic, medical, scientific and technological purposes; custom design and formulation in the nature of research, development, product evaluation of chemicals, assays and reagents for the diagnostics industry; custom design and formulation in the nature of research, development, product evaluation of chemicals, assays and reagents for separation and purification techniques; research and analysis for the diagnostics industry; technological services, namely, reading of results, processing of results, technical information, data sheets, and brochures relating to assays and lateral flow assays; technological and scientific research services relating to assays and lateral flow assays; lateral flow development of assays and lateral flow diagnostic testing services for medical, scientific and research purposes; development of lateral flow assays, lateral flow immunoassays and research into conjugate blocking technology; advisory, information and consultancy services relating to all of the aforesaid
Owner
- BBI Solutions OEM Limited, Cardiff, GB
- BBI Solutions OEM Limited, Cardiff, GB
- BBI Solutions OEM Limited, Cardiff, GB
Prosecution history
- 25 Apr 2025 — CANCELLED SEC. 8 (6-YR)
- 09 Oct 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 09 Oct 2018 — REGISTERED-PRINCIPAL REGISTER
- 30 Aug 2018 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 17 Jul 2018 — NOTICE OF ALLOWANCE CANCELLED
- 30 Aug 2018 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 17 Jul 2018 — TEAS DELETE 1(B) BASIS RECEIVED
- 13 Mar 2018 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Jan 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Jan 2018 — PUBLISHED FOR OPPOSITION
- 27 Dec 2017 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 08 Dec 2017 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 07 Dec 2017 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 07 Dec 2017 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 07 Dec 2017 — TEAS REQUEST FOR RECONSIDERATION RECEIVED